Zofenopri's and enalapril's influence as part of standard therapy on the dynamics of copeptin, MRproADM, troponin I and indicators of cardiohemodynamics and lipid profile in patients with acute myocardial infarction with concomitant obesity

Authors

  • Iermak A. S. Kharkiv National Medical University, Kharkov, Ukraine
  • Dunaieva I. P. SI "V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine", Kharkiv
  • Ryndina N. G. Kharkiv National Medical University, Kharkov, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2017.1.02

Keywords:

acute myocardial infarction, obesity, lisinopril, enalapril

Abstract

It were examined 75 patients with acute myocardial infarction (AMI) and obesity, among which 37 patients received enalapril and 38 patients received zofenopril as part of standart therapy. According to received results enalapril’s and zofenopril’s using showed expressive positive effect on the parametrs of cardiohaemodynamic, lipid profil, copeptin, MRproADM, troponin I, systolic blood pressure and diastolic blood pressure in patients with acute myocardial infarction and obesity. The most significant changes revealed in group of zofenopril in the treatment of patients with acute myocardial infarction and obesity.

References

Zalevskaja NG. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Serija: Medicina. Farmacija 2011; 14(10):260-267.

Semjonova IA, Semjonov AV, Ivanova TN, et al. Jekologija Cheloveka 2011; 5:31-35.

Fu G, Jia L, Wang Y, et al. J Int Cardiol 2012; 25(3):223-234. https://doi.org/10.1111/j.1540-8183.2011.00711.x

Bilovol OM, Kravchun PG, Kozhyn MI, et al. Diagnostyka, likuvannja ta profilaktyka osnovnyh kardiologichnyh zahvorjuvan’: navchal’nyj posibnyk: u 2 ch. Ch. 1, modul’ 2, Harkiv, 2010: 262 p.

Grundy SM. Arterioscler Thromb Vasc Biol 2008; 28:629-636. https://doi.org/10.1161/ATVBAHA.107.151092

Cornier MA, Dabelea D, Hernandez TL, et al. Endocr Rev 2008; 29:777-822. https://doi.org/10.1210/er.2008-0024

Doncov AV. Vestn Novyh Med Tehnologij 2010; 17(2):115-117.

Kokorin VA, Ljusov VA, Shajdjuk OJu. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Serija: Medicina. Farmacija 2011; 14(10):37-43.

Jermak OS, Kravchun PG, Ryndina NG, Rynchak PI. Bukovyn Med Visn 2015; 19(1):65-68.

Keller T, Tzikas S, Zeller T, et al. J Am Coll Cardiol 2010; 55:2096-2106. https://doi.org/10.1016/j.jacc.2010.01.029

Kataoka Y, Miyazaki S, Yasuda S, et al. J Cardiovasc Pharmacol 2010; 56(4):413-419. https://doi.org/10.1097/FJC.0b013e3181f15b45

Von Lueder Thomas G, Krum H. Cardiovasc Drugs Ther 2013; 27(2):171-179. https://doi.org/10.1007/s10557-012-6424-y

Majchuk EJu, Voevodina IV. Rus Med Zhurn 2005; 13(19):1287-1293.

Preobrazhenskij DV, Sidorenko BA, Bugrimova MA, et al. Rus Med Zhurn 2007; 4:3-10.

Evangelista S, Manzini S. J Int Med Res 2005; 33:42-54. https://doi.org/10.1177/147323000503300103

Gensh N. Medicine Review 2013; 1:32-38.

Downloads

Published

2017-02-20

How to Cite

Iermak, A. S., Dunaieva, I. P., & Ryndina, N. G. (2017). Zofenopri’s and enalapril’s influence as part of standard therapy on the dynamics of copeptin, MRproADM, troponin I and indicators of cardiohemodynamics and lipid profile in patients with acute myocardial infarction with concomitant obesity . Problems of Endocrine Pathology, 59(1), 18-24. https://doi.org/10.21856/j-PEP.2017.1.02

Issue

Section

CLINICAL ENDOCRINOLOGY